Last Updated: 09 Nov 2024
Executive Summary
Tharimmune Inc. (THAR) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immunotherapies for the treatment of cancer. Despite a challenging operating environment, the company has demonstrated strong financial performance with a trailing PE ratio of 0.118 and an EPS of $20.67. While the company's revenue and profitability metrics remain low, it has a significant cash position and a promising pipeline of drug candidates.
Company Overview
Tharimmune Inc. was founded in 2004 and is headquartered in Bridgewater, New Jersey. The company's lead product candidate, THIRA-C, is a monoclonal antibody that targets the CD19 antigen on B cells. THIRA-C is currently in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Tharimmune is also developing other immunotherapies, including THIRA-S and THIRA-T, which are in preclinical development.
Fundamental Analysis
Tharimmune's financial performance has been mixed. The company has reported losses in recent years, but its revenue has been growing. In 2023, the company reported a net loss of $14.9 million on revenue of $0.7 million. Tharimmune has a strong balance sheet with $69.7 million in cash and equivalents as of June 30, 2024.
Tharimmune's valuation metrics are attractive. The company's trailing PE ratio of 0.118 is well below the industry average. The company's price-to-book ratio of 0.417 is also low.
Technical Analysis
Tharimmune's stock price has been volatile in recent months. The stock reached a 52-week high of $81.38 in January 2023, but it has since fallen to $2.37. The stock's 50-day moving average is $2.523, and its 200-day moving average is $4.274.
Tharimmune's stock is currently trading below its 50-day and 200-day moving averages. This indicates that the stock is in a downtrend. The stock's relative strength index (RSI) is 30.37, which is below the neutral level of 50. This indicates that the stock is oversold.
Short Term Outlook
Tharimmune's stock is likely to remain volatile in the short term. The company's clinical trials are ongoing, and any positive or negative news could have a significant impact on the stock price. The stock's technical indicators suggest that it is in a downtrend, and this trend is likely to continue in the short term.
Long Term Outlook
Tharimmune's long-term outlook is more positive. The company has a promising pipeline of drug candidates, and it is well-funded. If Tharimmune's clinical trials are successful, the company could become a major player in the immunotherapy market.
Analyst Recommendations
Analysts are divided on Tharimmune's stock. One analyst has a hold rating on the stock, while another has a buy rating. The average analyst price target is $4.00.
Disclaimer
This report is for informational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.
